Novartis: Look To Alcon Instead [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
Novartis: Look To Alcon Instead Summary Novartis announced the Alcon spin-off to focus on pharma and generic drug business. Post-Alcon spin-off, NVS's potential margin erosion from competitive pressures might be highlighted. NVS appears overpriced relative to their prospects and is likely already priced for strong pipeline execution. Alcon might provide a better return for investors based on the turnaround of its operations and relatively better valuations. Investment Summary Investors got excited over the prospect of Novartis ( ALC Alcon Spin-off – The Background On 9 disclosed ALC is the global leader in the $23 billion eye market, dominated by 4-5 players. The company generates c. $7 billion in revenues through its primary segments: Surgical and Vision Care. Alcon’s Surgical segments markets equipment, disposables, and implants used in various ophthalmological surgical procedures, while its Vision Care segment generates sales from contact lenses and OTC eye care products. The Alcon
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Axmed raises $2M from Founderful to streamline drug supply chains in underserved markets [TechCrunch]TechCrunch
- Meet The Swiss Start-Up Bringing Medicines To Lower Income Nations [Forbes]Forbes
- Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive OfficerBusiness Wire
- CAR T Cell Therapy Market To Reach USD 39.9 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website